The present application provides Compound 1: ##STR00001##
or a pharmaceutically acceptable salt or amino acid conjugate thereof. The present invention relates to an FXR activator and to methods of making and using said compound.

The invention relates to an efficient and industrially applicable process for the preparation and purification of allopregnanolone and intermediates thereof without the assistance of column chromatography.

Described herein are new anti-cancer compounds and methods of using such compounds, acting through a new mechanism of action by simultaneous inhibition of leukemia inhibitory factor (LIF) and MDM2.

Described herein are new anti-cancer compounds and methods of using such compounds, acting through a new mechanism of action by simultaneous inhibition of leukemia inhibitory factor (LIF) and MDM2.

The present disclosure relates to methods of producing enantiodefined polycyclic ring compounds. More particularly, the present disclosure provides synthetic methods of producing biologically active enantiodefined steroidal compositions of both natural and unnatural (ent-) absolute stereochemistry. The present disclosure also relates to methods of using said steroidal compositions prepared from this method as biologically active (e.g., therapeutic) components in compositions and/or directly as human and/or animal therapeutics and medicines. The present disclosure further relates to methods of producing and using said steroidal compositions of matter in chemical, pharmacological, and biological studies and research.

The present disclosure relates to methods of producing enantiodefined polycyclic ring compounds. More particularly, the present disclosure provides synthetic methods of producing biologically active enantiodefined steroidal compositions of both natural and unnatural (ent-) absolute stereochemistry. The present disclosure also relates to methods of using said steroidal compositions prepared from this method as biologically active (e.g., therapeutic) components in compositions and/or directly as human and/or animal therapeutics and medicines. The present disclosure further relates to methods of producing and using said steroidal compositions of matter in chemical, pharmacological, and biological studies and research.

The present invention provides a process for preparation of deoxycholic acid or salt thereof; the process comprises the steps of reacting the compound of formula II to obtain a compound of formula III; the compound of formula III is converted to a compound of formula IV and the compound of formula IV is converted to deoxycholic acid. The present invention also provides a process for the purification of deoxycholic acid or salt thereof.

Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein (II), A, R.sup.1, R.sup.2, R.sup.3a, R.sup.4a, R.sup.4b, R.sup.5, R.sup.7a, and R.sup.7b are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia. ##STR00001##
(II)

Described herein are neuroactive steroids of the Formula (I):

##STR00001##

or a pharmaceutically acceptable salt thereof; wherein R.sup.1a and R.sup.1b are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.

The invention relates to new types of modulators of the cold menthol receptor TRPM8, to methods of modulating the TRPM8 receptor using these modulators; and in particular the use of the modulators for inducing a sensation of coldness; and also the articles and compositions produced using these modulators.